Company intelligence / Profile preview

Inretio

Sderot, Southern District, Israelinretio.co.il ↗

Ownership: Private
Development stage: Phase 1

Overview

Inretio has developed the PREVA® mechanical thrombectomy device for ischemic stroke. The device completed a successful Good Laboratory Practice (GLP) study with 100% clot removal in all cases and has since completed three human clinical trials as of August 2024. The company reports improved safety and efficacy compared to existing devices, with ongoing progress toward FDA 510K clearance.[4][6][7]

Therapeutic areas: Cardiovascular
Modalities: Device (Mechanical thrombectomy device)
Industry: Surgical Medical Devices

Drug pipeline

1 asset

PREVA

Phase 1

Indications: Ischemic stroke

Partnerships

Therma Bright Inc. holds an equity stake (~8.44%) and has provided investment and strategic support.

Beyond the preview

Go deeper on Inretio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Inretio.

Explore the full profile